Lung | Interview with Jamie E Chaft, MD

1:11:32
 
Share
 

Manage episode 229585822 series 1464173
By Dr Neil Love. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.

Lung Cancer Update – Part 2: Our interview with Dr Chaft highlights the following topics as well as cases from her practice:

  • Case: A 54-year-old woman and never smoker presenting with arthralgias, digital clubbing and leg edema is diagnosed with Stage IIIA NSCLC and an EGFR exon 19 deletion: 0m0s
  • Evaluation of anti-PD-1/PD-L1 antibodies as neoadjuvant therapy for NSCLC: 3m2s
  • Predictors of clinical benefit from neoadjuvant therapy with immune checkpoint inhibitors: 6m41s
  • Selection of patients for neoadjuvant therapy with anti-PD-1/PD-L1 antibodies: 7m52s
  • Choice of adjuvant therapy for patients with NSCLC and an EGFR tumor mutation: 12m10s
  • Risks and benefits with osimertinib in the adjuvant setting: 14m38s
  • Status of the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials (ALCHEMIST) for patients with early-stage lung cancer: 17m31s
  • Results of the Phase III SELECT trial of adjuvant erlotinib for resected NSCLC with an EGFR tumor mutation: 19m5s
  • Case: A 59-year-old man and former smoker with unresectable, Stage III NSCLC receives durvalumab as consolidation therapy after chemoradiation therapy: 22m58s
  • Management of superior vena cava syndrome in patients with lung cancer: 25m23s
  • Activity and tolerability of durvalumab as consolidation therapy: 27m50s
  • Perspective on the results of the PACIFIC trial of durvalumab after chemoradiation therapy for Stage III NSCLC: 29m15s
  • Recognition and management of pneumonitis associated with durvalumab/radiation therapy: 30m53s
  • Impact of baseline steroids on the efficacy of PD-1/PD-L1 blockade in patients with NSCLC: 35m7s
  • Effects of tumor mutations and PD-L1 expression on response to checkpoint inhibitors: 36m54s
  • Case: A 68-year-old woman and smoker experiences recurrent colitis after receiving nivolumab for metastatic NSCLC: 40m11s
  • Incidence and mitigation of diarrhea and colitis associated with checkpoint inhibitors: 42m45s
  • Management of metastatic nonsquamous NSCLC in the first-line setting: 46m0s
  • Perspective on the results of the Phase III IMpower150 study: 49m47s
  • Selection of first-line therapy for patients with metastatic squamous NSCLC: 53m3s
  • Risks and benefits of nivolumab with ipilimumab for metastatic NSCLC: 54m44s
  • Therapeutic approach for patients with metastatic small cell lung cancer: 58m18s
  • Duration of therapy with immune checkpoint inhibitors: 1h0m23s
  • Pseudoprogression and hyperprogression associated with immune checkpoint inhibitors: 1h2m18s
  • Case: A 64-year-old woman with metastatic NSCLC and an ALK rearrangement receives alectinib after developing intolerance to crizotinib: 1h4m40s
  • Efficacy and side effects of the ALK inhibitors alectinib, brigatinib and lorlatinib: 1h7m21s

Select publications

2183 episodes